Pneumococcus (Streptococcus pneumoniae), a pathogenic bacterium, is the leading cause of serious illness worldwide. It is the major cause of pneumonia, blood infections, meningitis, sinusitis, and middle ear infections (otitis media). Pneumococcal infections affect children younger than five years and older people (65 years and older), and it is among the leading infectious disease. It kills almost 1.6 million people (including over 800,000 children under five years) every year. It can be prevented by vaccination and involves the introduction of a dead or weakened antigen into the human body. This produces lymphocytes to counter the infection and any future invasions by that antigen.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Pneumococcal vaccine: Overview

Vaccine approval process

PART 06: Market landscape

Market overview

Five forces analysis

Market segmentation by composition

Global PCV market

Market overview

Global PPV market

Market overview

PART 07: Geographical segmentation

Pneumococcal vaccine market in Americas

Pneumococcal vaccine market in EMEA

Pneumococcal vaccines market in APAC

PART 08: Market drivers

Inclusion in NIP

Broad serotype coverage

Global action plans for pneumonia vaccines

PART 09: Impact of drivers

PART 10: Market challenges

Inadequate vaccine coverage

Require cold storage

High risk and cost involved in vaccine development

Stringent regulatory guidelines

PART 11: Impact of drivers and challenges

PART 12: Market trends

Expansion of marketing territories

Emergence of protein-based combination pneumococcal

vaccines

AMC for pneumococcal vaccines

Bio-terrorism

Public–private initiatives

PART 13: Vendor landscape

Competitive scenario

Key news

Pfizer

Sanofi

GSK

Merck

Other prominent vendors

PART 14: Appendix

List of abbreviations

PART 15: Explore Technavio